HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS: A SEER-MEDICARE ANALYSIS

被引：0
|
作者：
Stein, E. M. [1 ]
Latremouille-Viau, D. [2 ]
Shi, S. [2 ]
Guerin, A. [2 ]
Wu, E. [3 ]
Bonifacio, G. [4 ]
Cao, X. [4 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] Anal Grp Inc, Boston, MA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG20
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [11] Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS)
    Uno, Hajime
    Cronin, Angel M.
    Wadleigh, Martha
    Schrag, Deborah
    Abel, Gregory A.
    [J]. LEUKEMIA RESEARCH, 2014, 38 (12) : 1420 - 1424
  • [12] HEALTHCARE UTILIZATION AND COSTS IN LUNG CANCER PATIENTS WITH PRE-EXISTING COPD AMONG SEER-MEDICARE BENEFICIARIES
    Shah, S.
    Blanchette, C. M.
    Arthur, S.
    Coyle, J. P.
    Kowalkowski, M.
    Howden, R.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A360 - A360
  • [13] HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS AMONG PREVIOUSLY-TREATED PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC): A RETROSPECTIVE ANALYSIS OF SEER-MEDICARE LINKED CLAIMS
    Rai, P.
    Paratane, D.
    Turkistani, F.
    Min, J.
    Rajagopalan, K.
    Hu, X.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S386 - S386
  • [14] Mortality and hospitalization in myelodysplastic syndromes (MDS) using the SEER-Medicare linked database
    Lindquist, K.
    Danese, M.
    Knopf, K.
    Mikhael, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [15] Pre-existing symptoms, resource utilization, and healthcare costs prior to diagnosis of neuroendocrine tumors: A SEER-Medicare database study.
    Shen, Chan
    Chu, Yiyi
    Dasari, A.
    Zhou, Shouhao
    Halperin, Daniel M.
    Xu, Ying
    Shih, Ya-Chen T.
    Yao, James C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [16] Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review
    Yang, Jiayu
    Choi, Nora
    Mozessohn, Lee
    Sanford, David
    Paulson, Kristjan
    Houston, Donald S.
    Rimmer, Emily
    Lother, Sylvain
    Mendelson, Asher
    Garland, Allan
    Buckstein, Rena
    Hay, Annette E.
    Zarychanski, Ryan
    Houston, Brett L.
    [J]. BLOOD, 2022, 140 : 12317 - 12318
  • [17] Prognostic value of the SEER-Medicare myelodysplastic syndromes risk score for a contemporary cohort of patients with MDS.
    Afzal, Amber
    Fiala, Mark A.
    Jacoby, Meagan
    Walter, Matthew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18762 - E18762
  • [18] Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents
    Garcia-Manero, Guillermo
    Matsuno, Rayna K.
    McBride, Ali
    Mohammed, Hina
    Idryo, Danny
    Broome, Ronda
    Herriman, Autumn
    Johnson, Tiffany
    Wilkinson, Kristiana
    Schrag, Andrew
    Johanson, Colden
    Izano, Monika
    Makinde, Adeola
    Mukherjee, Sudipto
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : e283 - e292
  • [19] Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
    Zeidan, Amer M.
    Kharfan-Dabaja, Mohamed A.
    Komrokji, Rami S.
    [J]. CURRENT OPINION IN HEMATOLOGY, 2014, 21 (02) : 123 - 130
  • [20] Meta-analysis on hypomethylating agents in myelodysplastic syndromes
    Herbst, Christine
    Baner, Kathrin
    Kreuzer, Karl-Anton
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 342 - 343
12345